The abstract is read at the publisher; the summary is JClub's.
Genomic heterogeneity plus baseline tumor burden predicts durable response to first-line BRAFi/MEKi in 155 patients with BRAF-mutant metastatic melanoma, with high precision and specificity.
- Why it matters: Most BRAF-mutant metastatic melanoma patients eventually progress on targeted therapy, but a durable subset exists; identifying biomarkers could improve treatment selection.
- What they did: Pre-treatment tumor samples from 155 patients underwent whole-exome sequencing, and spatial immunohistochemistry was performed in a subset (n = 47) to quantify CD8+ T-cell infiltration.
- The result: High intratumoral CD8+ T-cell infiltration predicted prolonged survival on BRAF-targeted therapy, and analogous immunotherapy-treated patients were not durable responders, supporting targeted-therapy specificity.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.